Skip to content

Acute & Chronic Post-mastectomy Pain: Can PECS Block Alter the Geography?

Acute & Chronic Post-mastectomy Pain: Can PECS Block Alter the Geography?

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04443894
Enrollment
40
Registered
2020-06-23
Start date
2020-05-20
Completion date
2023-12-31
Last updated
2020-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immediate and Chronic Pain After Mastectomy Managed With PECS Block or Local Infiltration

Keywords

pain, mastectomy, PECS

Brief summary

Post mastectomy pain management is of crucial importance for patients' rehabilitation and quality of life. PECS block is used for acute and chronic post mastectomy pain management. Surgical infiltration is also used in this field. Patients in our study are divided in two groups receiving PECS block or surgical infiltrationbefore incision. Multimodal analgesia is indispensable according to recent guidelines for enhanced postoperative recovery. Pain scores will be assessed during the first 24h postoperatively and at 3 months after surgery.

Detailed description

Patients are randomly assigned to 2 groups, PECS block or surgical infiltration group. Patients assigned to PECS group will receive 30cc of ropivacaine 0,375% where 10cc will be injected between pectoralis major and pectoralis minor and 20cc between pectoralis minor and serratus anterior muscle under ultrasound guidance. Patients assigned to surgical infiltration group will receive 30cc of ropivacaine 0,375% injected by the surgeon. Local aneshetic is administered in both groups after the induction of general anesthesia and before incision. Pain will be assessed at 1, 12, 24h after surgery and at three months after surgery communicating by telephone. Post operative analgesia includes paracetamol 1gr, parecoxib 40 mg (as required) and tramadol as rescue analgesia (1 mg/kg iv up to 3 times daily). Chronic pain will be assessed after 3 months as for prevalence and neuropathic characteristics.

Interventions

PECS block is performed at the side of surgery (II) before incision with ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).

OTHERlocal infiltration

local infiltration of the surgical wound before incision with πwith ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).

Sponsors

Attikon Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

PATIENT OUTCOME ASSESSOR

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* over 18 years of age * ASA physical status I-III * elective partial mastectomy

Exclusion criteria

* refusal of patient participation or inability to participate to the study * known allergic reaction to drugs included in the study design * contraindiations of performance of peripheral regional anesthesia * diabetes melitus or known neurological disorder * chronic pain disorders under therapy with opioids or other analgesic drugs for chronic pain * all male patients * all patients not speaking the Greek language

Design outcomes

Primary

MeasureTime frameDescription
intensity of acute postoperative pain24 hoursintensity of acute postoperative pain, numeric rating scale 0-10

Secondary

MeasureTime frameDescription
intensity of chronic pain3 monthsintensity of chronic pain with numeric rating scale 0-10
Prevalence of chronic neuropathic pain3 monthsPrevalence of chronic pain at the site of surgery, measured with the LANSS questionnaire

Countries

Greece

Contacts

Primary ContactEleftheria Soulioti, MD,PhD
eleftheriasoulioti@ymail.com00306946745366
Backup ContactChrysanthi Batistaki, MD,PhD
chrysabatistaki@yahoo.gr00302105832371

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026